Long-term Extension Study of Ligelizumab in Food Allergy

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Food Allergy

In brief

This was an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who completed a ligelizumab Phase III study in food allergy.

Key facts

Study ID
NCT05678959
Run by
Novartis Pharmaceuticals
People needed
163
Starts
2023-04-27
Expected to finish
2025-03-06
Last updated by the study team
2026-01-13

Who can join

Age: 6 and older, up to 57. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.